Thyroid disorder — all decisions

The Board remands the matter for a new VA examination to determine the current severity of the Veteran's service-connected nontoxic left single thyroid nodule.

The Board granted the restoration of service connection for hypertension, as the grant was not clear and unmistakable error. The claims for diabetes, hypothyroidism, and bilateral peripheral neuropathy were remanded due to duty to assist errors.

The Board granted a 70 percent rating for PTSD effective April 9, 2019, and denied an earlier effective date for uterine polyps and fibroids with uterine bleeding.

The Board denied the Veteran's appeal for a rating in excess of 30 percent for hypothyroidism since February 14, 2023.

All claims for service connection and effective date were dismissed due to lack of new evidence or legal basis.

The Board denied the Veteran's claims for revision of a February 1997 rating decision on the basis of clear and unmistakable error (CUE) due to the failure to adjudicate service connection for hyperthyroidism, traumatic brain injury, and a higher initial rating for gastroesophageal reflux disease.

The appeal for service connection for a thyroid condition and a bilateral foot condition (claimed as cold weather flatfoot) was dismissed due to a prohibited concurrent election. The appeal for right ear hearing loss was denied.

The Board denied service connection for bilateral hearing loss and hypertension, but granted service connection for tinnitus. The claim for multiple thyroid nodules was also denied.

The Board denied service connection for erectile dysfunction with hypogonadism, hypertension, and tinnitus due to insufficient evidence of current disability or functional impairment. The claims for these conditions were remanded for further development.

The Board remands the claims for service connection for menstrual disability, hyperthyroidism, multinodular thyroid, and scars, status/post thyroidectomy due to inadequate VA opinions regarding their etiology.

The Board granted an effective date of January 31, 2018, for the grant of service connection of hypertension and obstructive sleep apnea but denied earlier effective dates for other conditions.

The Board denied service connection for a thyroid disability, finding that the condition did not onset in or during active service and was not aggravated by subsequent service.

The Board granted service connection for hyperthyroidism and denied service connection for glaucoma, sleep apnea, lung condition (including COPD and asthma), GERD, breast cancer, IBS, blood clots, and heart condition. The claims for bilateral hearing loss and tinnitus were remanded.

The Board denied service connection for chronic urinary tract infections, diabetes mellitus, benign prostatic hypertrophy, hyperparathyroidism and hypercalcemia, hypertension, and special monthly compensation based on aid and attendance/housebound status.

The Board denied service connection for hearing loss and tinnitus, while remanding the claims for coronary artery disease (CAD), prostate cancer, obstructive sleep apnea, cataracts, and thyroid removal due to a duty to assist error.

The Board granted service connection for obstructive sleep apnea as secondary to the Veteran's service-connected tinnitus, but remanded the claim for thyroid cancer due to a pre-decisional duty to assist error.

The Board denied the veteran's claim for service connection for a thyroid condition, finding that there is no medical evidence linking the condition to his active duty service or herbicide exposure.

The Board denied service connection for decreased memory due to the absence of a current disability, while remanding claims for non-alcoholic fatty liver with cirrhosis, hypothyroidism, hypertension, and obstructive sleep apnea (OSA) for further development.

The Board granted service connection for hypothyroidism, resolving reasonable doubt in the Veteran's favor. The issues of entitlement to service connection for kidney disease and left ear hearing loss were remanded.

The Board denied service connection for coronary artery disease, prostate cancer, and hypothyroidism prior to August 10, 2022.